Literature DB >> 15297081

Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial.

Prashant K Jain1, Clare E McNaught, Alexander D G Anderson, John MacFie, Charles J Mitchell.   

Abstract

BACKGROUND & AIMS: Infective complications are a common cause of mortality and morbidity in critically ill patients. Many factors affect sepsis, one of which is gut barrier function. The aim of this study was to determine whether the oral administration of a synbiotic preparation could alter gut barrier function in critically ill patients and thus reduce sepsis.
METHODS: A total of 90 patients admitted to an intensive care unit (ICU) were randomised to receive either synbiotic or placebo preparations (45 into each group). The synbiotic preparation consisted of Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus and Lactobacillus bulgaricus (probiotics) with oligofructose (prebiotic). Gut barrier function was assessed by measurement of intestinal permeability (lactulose/rhamnose test) and culture of nasogastric aspirate on days 1 and 8. All septic complications and mortality were recorded.
RESULTS: There were no differences between the groups in terms of age, sex, APACHE II or POSSUM scores. After 1 week of therapy, patients in the synbiotic group had a significantly lower incidence of potentially pathogenic bacteria (43% versus 75%, P = 0.05) and multiple organisms (39% versus 75%, P = 0.01) in their nasogastric aspirates than controls. There were no significant differences between the groups in terms of intestinal permeability, septic complications or mortality.
CONCLUSIONS: The administration of synbiotic in critically ill patients favourably altered the microbial composition of the upper gastrointestinal tract but had no effect on intestinal permeability and was not associated with measurable clinical benefit. Copyright 2003 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297081     DOI: 10.1016/j.clnu.2003.12.002

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  35 in total

1.  Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial.

Authors:  Damien Barraud; Claire Blard; François Hein; Olivier Marçon; Aurélie Cravoisy; Lionel Nace; François Alla; Pierre-Edouard Bollaert; Sébastien Gibot
Journal:  Intensive Care Med       Date:  2010-05-26       Impact factor: 17.440

Review 2.  Do probiotics have a therapeutic role in gastroenterology?

Authors:  Jimmy K Limdi; Catherine O'Neill; John McLaughlin
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

3.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  A question of survival? Interaction between probiotics and the gastrointestinal tract.

Authors:  Herbert Lochs
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Controversial results with use of probiotics in critical illness: contradictory findings from large multicenter trial.

Authors:  Jeremy R Stapleton; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2009-08

Review 6.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 7.  Impact of Soluble Fiber in the Microbiome and Outcomes in Critically Ill Patients.

Authors:  Carla Venegas-Borsellino; Minkyung Kwon
Journal:  Curr Nutr Rep       Date:  2019-12

8.  Ventilation-associated pneumonia and probiotics: many clues do not make evidence. Response to comments by Colombo and Codazzi.

Authors:  Juan Zeng; Chun-Ting Wang
Journal:  Intensive Care Med       Date:  2016-07-28       Impact factor: 17.440

Review 9.  Probiotics for preventing ventilator-associated pneumonia.

Authors:  Lulong Bo; Jinbao Li; Tianzhu Tao; Yu Bai; Xiaofei Ye; Richard S Hotchkiss; Marin H Kollef; Neil H Crooks; Xiaoming Deng
Journal:  Cochrane Database Syst Rev       Date:  2014-10-25

Review 10.  The interplay between fiber and the intestinal microbiome in the inflammatory response.

Authors:  Shiu-Ming Kuo
Journal:  Adv Nutr       Date:  2013-01-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.